BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: A global pharmaceutical company operating through four segments: Pharmaceuticals, Oncology Therapeutics Network (OTN), Nutritionals, and Other Healthcare. The company is currently navigating significant product exclusivity losses, restructuring initiatives, and extensive legal proceedings.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales increased 1% in the third quarter and 5% in the first nine months compared to 2003. Growth was driven by foreign exchange benefits and new product launches (ABILIFY, ERBITUX, REYATAZ), partially offset by volume declines due to exclusivity losses (GLUCOPHAGE, PRAVACHOL, PARAPLATIN).
• Profitability: Net earnings decreased 16% in the third quarter and 14% in the first nine months. Earnings before minority interest and income taxes dropped 15% (Q3) and 10% (9 months).
• Unusual Items:
  • Legal Reserves: A $404 million litigation settlement expense was recorded in the first nine months of 2004, primarily related to wholesaler inventory/accounting matters ($320 million) and PLATINOL antitrust litigation ($50 million).
  • Divestiture Gain: A $316 million pre-tax gain was recognized from the sale of the Mead Johnson Adult Nutritional business to Novartis.
  • Restructuring: Charges of $75 million were recorded in the first nine months for workforce reductions and facility closures.
  • Acquisition Write-off: A $63 million write-off of acquired in-process research and development occurred following the acquisition of Acordis Speciality Fibres.
• Margins: Gross margin percentages declined to 61.3% (Q3) and 62.0% (9 months) from 64.1% and 64.0% in the prior year, respectively, due to product mix shifts and exclusivity losses.

Guidance, Outlook, and Risks

• Exclusivity Losses: Management expects substantial incremental sales losses in 2005, 2006, and 2007 due to the expiration of patents on key products including PRAVACHOL (U.S. 2006), PARAPLATIN (U.S. 2004), and GLUCOPHAGE franchise.
• Growth Drivers: Future growth is expected from PLAVIX, AVAPRO/AVALIDE, ABILIFY, REYATAZ, and ERBITUX. Late-stage pipeline compounds include muraglitazar (diabetes), abatacept (rheumatoid arthritis), and entecavir (hepatitis B).
• Legal Risks: The company faces significant pending litigation regarding PLAVIX patent validity (decision expected H1 2005), product liability (SERZONE, PPA, STADOL NS), and pricing practices. Management believes the aggregate impact of legal matters beyond current reserves is reasonably likely to be material to results of operations and cash flows.
• Tax Outlook: The American Jobs Creation Act of 2004 may allow the company to deduct 85% of eligible dividends from non-U.S. subsidiaries if reinvested in the U.S. The company anticipates accruing a tax provision in Q4 2004.
• Internal Controls: A reportable condition regarding income tax accounting controls was identified by auditors. Remediation is ongoing and expected to be completed by year-end 2004.

Investor Verification Checklist

• PLAVIX Litigation Outcome: Monitor the U.S. District Court decision expected in the first half of 2005 regarding the composition of matter patent, which could trigger generic competition before 2011.
• Legal Reserve Adequacy: Verify if the $470 million total reserve for wholesaler inventory/accounting matters and the $134 million for pricing practices are sufficient given ongoing government investigations.
• Exclusivity Impact: Track the rate of sales decline for PRAVACHOL and the GLUCOPHAGE franchise to assess if exclusivity losses are accelerating faster than anticipated.
• Product Launch Success: Confirm sales performance of new products (ERBITUX, ABILIFY, REYATAZ) to ensure they offset the revenue gap from lost exclusivity.
• Internal Control Remediation: Confirm the completion of remediation for the income tax accounting reportable condition before the 2004 10-K filing.